MDM4 is altered in 1.35% of malignant solid tumor patients [3].

MDM4 is an inclusion criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain MDM4 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (7 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].

MDM4 is altered in 1.24% of prostate adenocarcinoma patients [3].

MDM4 is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain MDM4 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].

MDM4 is altered in 0.62% of medulloblastoma patients [3].

MDM4 is an inclusion criterion in 8 clinical trials for medulloblastoma, of which 8 are open and 0 are closed. Of the trials that contain MDM4 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 4 (1 open) [4].

MDM4 is altered in 1.22% of prostate carcinoma patients [3].

MDM4 is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain MDM4 status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].

MDM4 is altered in 2.81% of breast carcinoma patients [3].

MDM4 is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MDM4 status and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (0 open) [4].

MDM4 is altered in 0.52% of ovarian carcinoma patients [3].

MDM4 is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain MDM4 status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [4].

MDM4 is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain MDM4 status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

MDM4 is altered in 0.76% of cervical carcinoma patients [3].

MDM4 is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MDM4 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

MDM4 is altered in 0.57% of colorectal carcinoma patients [3].

MDM4 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MDM4 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

MDM4 is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain MDM4 status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

MDM4 is altered in 4.55% of atypical teratoid/rhabdoid tumor patients [3].

MDM4 is an inclusion criterion in 2 clinical trials for atypical teratoid/rhabdoid tumor, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and atypical teratoid/rhabdoid tumor as inclusion criteria, 2 are phase 1 (2 open) [4].

MDM4 is altered in 1.82% of fallopian tube carcinoma patients [3].

MDM4 is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [4].

MDM4 is altered in 1.98% of endometrial carcinoma patients [3].

MDM4 is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MDM4 is altered in 1.29% of central nervous system embryonal neoplasm patients [3].

MDM4 is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MDM4 is altered in 1.01% of non-small cell lung carcinoma patients [3].

MDM4 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MDM4 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

MDM4 is altered in 0.77% of head and neck squamous cell carcinoma patients [3].

MDM4 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MDM4 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

MDM4 is altered in 0.53% of non-hodgkin lymphoma patients [3].

MDM4 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MDM4 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

MDM4 is altered in 0.32% of adenocarcinoma of the gastroesophageal junction patients [3].

MDM4 is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MDM4 is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MDM4 is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MDM4 is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

MDM4 is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

MDM4 is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

MDM4 is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

MDM4 is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

MDM4 is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain MDM4 status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

MDM4 is altered in 8.33% of penile carcinoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM4 status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MDM4 is altered in 5.26% of glioblastoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 4.43% of malignant glioma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 4.06% of diffuse glioma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 3.37% of anaplastic astrocytoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 3.45% of rhabdoid tumor patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 3.05% of malignant central nervous system neoplasm patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 2.41% of retinoblastoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for retinoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and retinoblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 1.75% of anaplastic ependymoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 1.24% of anaplastic oligodendroglioma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 1.23% of bladder urothelial carcinoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MDM4 is altered in 1.18% of urothelial carcinoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MDM4 is altered in 1.13% of cholangiocarcinoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MDM4 is altered in 1.11% of small cell lung carcinoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MDM4 is altered in 1.03% of soft tissue sarcoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MDM4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MDM4 is altered in 1.09% of high-grade glioma, NOS patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 0.97% of diffuse large B-cell lymphoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 0.71% of esophageal carcinoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MDM4 is altered in 0.58% of malignant intestinal neoplasm patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MDM4 is altered in 0.52% of malignant esophagogastric neoplasm patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MDM4 is altered in 0.9% of malignant small intestinal neoplasm patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MDM4 is altered in 0.71% of gastrointestinal stromal tumor patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MDM4 is altered in 0.48% of high grade ovarian serous adenocarcinoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM4 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MDM4 is altered in 0.38% of gastric carcinoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 0.38% of malignant gastric neoplasm patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MDM4 is altered in 0.62% of malignant ovarian epithelial tumor patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MDM4 is altered in 0.29% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 0.34% of acute myeloid leukemia patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 0.41% of lymphoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is altered in 0.33% of pancreatic adenocarcinoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MDM4 is altered in 0.33% of pancreatic carcinoma patients [3].

MDM4 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for acute biphenotypic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and acute biphenotypic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM4 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for extrarenal rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and extrarenal rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for hepatoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and hepatoblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for intracranial primitive neuroectodermal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and intracranial primitive neuroectodermal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for rhabdoid tumor of the kidney, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and rhabdoid tumor of the kidney as inclusion criteria, 1 is phase 1 (1 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM4 status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MDM4 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MDM4 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].